Articles by James Calloway
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Inditex Initiates Share Repurchase Ahead of March Earnings
Inditex shares edged higher Friday after announcing a €180 million buyback program for employee incentives, with full-year results due March 11.
Thermo Fisher Shares End Week Lower Amid Research Funding Concerns
Thermo Fisher Scientific closed Friday at $542.83, down 6.7% for the week as investors weigh pressure from academic research funding cuts. The company's 2026 outlook projects adjusted earnings of $24.22 to $24.80 per share.
T-Mobile Shares Decline Ahead of Key Earnings and Strategy Update
T-Mobile US stock fell 2.2% on Friday, underperforming the broader market and telecom peers as investors await the company's quarterly results and capital markets day presentation on February 11.
China Mobile Faces VAT Hike Impact as Inflation Data and Earnings Loom
China Mobile's A-shares trade near 95 yuan as a VAT increase on telecom services pressures profits. Investors await February inflation figures and the company's March earnings report.
L'Oréal Shares Dip Ahead of Annual Results; China Demand, Margins in Focus
L'Oréal shares closed slightly lower ahead of its 2025 annual results release. Analysts anticipate sales near €44.1 billion, with investor attention on guidance and Chinese market performance.
Hermès Shares Steady at €2,055 Ahead of Key Annual Report
Hermès International shares closed at €2,055, up 0.3%, as investors await the luxury group's 2025 annual results on February 12. Focus will be on demand trends, margin resilience, and regional performance.
Nestle Shares Gain Ahead of Key 2025 Results and 2026 Outlook
Nestle shares rose 0.6% to CHF 78.89 on Friday, with investors focused on the company's upcoming full-year results and strategic outlook scheduled for February 19.



